November 16–19 | London
Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend the Jefferies Global Healthcare Conference 2026 in London. He will participate in the China Biotech Panel on November 18 from 11:00 to 11:50 AM, where he will deliver a keynote speech and join fellow panelists for an in-depth discussion on cutting-edge AI-driven drug discovery and the latest innovation dynamics within China's biopharmaceutical industry.
About Jefferies Global Healthcare Conference 2026 Now in its 17th year, the Jefferies Global Healthcare Conference (London) is the largest healthcare-dedicated investment conference in Europe. Taking place from November 16 to 19, 2026, at The Waldorf Hilton in London, the event brings together over 800 global public and private healthcare companies and more than 4,100 attendees, facilitating over 15,000 meetings (including 9,500 one-on-one institutional investor meetings). Spanning biotechnology, pharmaceuticals, medical devices, and healthcare services, the conference focuses on near- to medium-term investment opportunities and key trends shaping the global healthcare landscape. Attendance is by invitation only for participants pre-registered through a Jefferies representative. Serving as the anchor event for London Life Sciences Week (November 15–20), the conference joins dozens of concurrent satellite events to form Europe’s premier annual hub for life sciences investment and collaboration.
November 17 | London
Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend the UBS Biopharma Conference in London, where he will join a panel discussion titled China Biotech on November 17 from 12:40 to 1:10 PM.
Against the backdrop of sustained global investor focus on the evolving role of Chinese biotech, this dedicated session provides a platform for direct dialogue between industry leaders and capital markets on emerging trends. While traditional biotech valuation is anchored in clinical stages, addressable indication markets, and peak sales projections, a substantial portion of an AI platform company's value lies not in any single molecule, but in its repeatable capacity to consistently generate the next candidate.
About UBS Biopharma Conference Hosted by UBS Group, the inaugural UBS Global Biopharma Conference will be held from November 16 to 17, 2026, at Rosewood London. Centered around corporate presentations and one-on-one investor meetings, the event convenes leading global biopharmaceutical companies, institutional investors, and industry experts to discuss the latest trends in biopharma innovation, capital allocation, and cross-border collaboration. "China Biotech" stands as one of the core themes of this year's conference, reflecting growing international investor appetite for Chinese innovative assets. As a newly established premier investor platform by UBS in the healthcare sector, the conference upholds the consistent positioning of UBS's global healthcare conference series—providing a high-caliber setting for in-depth dialogue between public company management and long-term capital.
November 18–21 | Dubai
Alex Aliper, PhD , Co-Founder and President of Insilico Medicine, has been invited to attend Dubai Future Week in Dubai. On November 20, from 9:10 to 9:45 AM , he will deliver a keynote speech titled "Generative AI and Laboratory Automation for Drug Discovery and Longevity." During the session, Dr. Aliper will share in-depth insights into how Insilico Medicine integrates generative AI algorithms with fully automated robotic laboratories into a closed-loop system—breaking through traditional drug R&D bottlenecks and accelerating a paradigm shift from anti-aging target discovery to innovative pipeline advancement.
About Dubai Future Week Hosted by the Dubai Future Foundation, Dubai Future Week will take place from November 18 to 21, 2026, at Emirates Towers and the Museum of the Future. Held under the theme "For the Human of the Future," the event explores five core pillars: how we will live, think, innovate, feel, and do business. Expecting to attract over 10,000 attendees across 75 sessions, Dubai Future Week brings together platforms such as the Dubai Future Forum and Dubai AI Week. Through mainstage keynotes, prototype showcases, and policy roundtables, it aims to translate forward-looking discussions into actionable collaborations and tangible solutions.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com